Class / Patent application number | Description | Number of patent applications / Date published |
514428000 | Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding | 38 |
20080207735 | 1-Amino Linked Compounds - The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C | 08-28-2008 |
20080207736 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists - The invention provides compounds of formula I: | 08-28-2008 |
20080207737 | Methods for the Treatment of Hyperhidrosis - The present invention relates in general to methods of treating sweating disorders and in particular to topical compositions for the treatment of hyperhidrosis. The methods of the present invention relate to the topical application of a composition comprising a therapeutically effective amount of oxybutynin, tolterodine or a substituted benzamide such as sulpiride. | 08-28-2008 |
20080262075 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists - This invention relates to pyrrolidine derivatives, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated through muscarinic receptors are also provided. | 10-23-2008 |
20090062374 | DEUTERIUM-ENRICHED LASOFOXIFENE - The present application describes deuterium-enriched lasofoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090203763 | SUBSTITUTED BENZHYDRYLETHERS - Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof. | 08-13-2009 |
20090286848 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES - The present invention is directed to the compounds of formula | 11-19-2009 |
20090292000 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS - Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound. | 11-26-2009 |
20090312392 | Amino ceramide-like compounds and therapeutic methods of use - The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels. | 12-17-2009 |
20090326039 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. | 12-31-2009 |
20100022616 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 01-28-2010 |
20100035959 | Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same - Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis. | 02-11-2010 |
20100105755 | SUBSTITUTED BENZAMIDE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new substituted benzamide modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof. | 04-29-2010 |
20100222406 | T Type Calcium Channel Blockers and the Treatment of Diseases - The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R | 09-02-2010 |
20100317712 | Estrogen Agonists/Antagonists For Preventing Breast Cancer - Compounds of this formula | 12-16-2010 |
20110009465 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 01-13-2011 |
20110230540 | MANASSATIN COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - Provided are manassantin compounds and methods of using the compounds. Provided are methods of treating a disease, the method comprising administering a compound according to Formula I. Further provided are pharmaceutical compositions comprising compounds according to Formula I. Also provided are methods of inhibiting HIF-1 in a cell, the methods comprising administering to the cell a compound according to Formula I. | 09-22-2011 |
20110257243 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 10-20-2011 |
20110275694 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 11-10-2011 |
20110319468 | CYCLIC AMINE COMPOUNDS - Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof | 12-29-2011 |
20120010265 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 01-12-2012 |
20120122951 | SKIN-WHITENING AGENT AND COSMETIC METHOD FOR WHITENING SKIN - The development of a skin-whitening agent which has a lower molecular weight, can be synthesized through a fewer steps and can be produced at low cost has been demanded. Thus, it is provided by the present invention a skin-whitening agent including one or more compounds selected from the group consisting of 4-cis-hydroxyproline and its derivative and/or its salt, a skin-whitening composition for external formulation to the skin, a cosmetic composition and a pharmaceutical composition, each of which contains the skin-whitening agent of the invention, and a cosmetic method for whitening the skin, which includes a step of administering one or more compounds selected from the group consisting of 4-cis-hydroxyproline and its derivative and/or its salt. In the skin-whitening agent and the cosmetic method for whitening the skin of the invention, the 4-cis-hydroxyproline may be 4-cis-L-hydroxyproline and/or 4-cis-D-hydroxyproline. | 05-17-2012 |
20120129909 | 2-AMINO-2-PHENYL-ALKANOL DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - Ester derivatives of 2-amino-2-phenyl-alkanol of general formula (I) in which: R | 05-24-2012 |
20120178790 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 07-12-2012 |
20120264804 | T TYPE CALCIUM CHANNEL BLOCKERS AND THE TREATMENT OF DISEASES - The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor blocks a splice variant of an α1H isoform of T type calcium channels. | 10-18-2012 |
20130085172 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND - The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases. | 04-04-2013 |
20130137746 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 05-30-2013 |
20130178509 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 07-11-2013 |
20140018407 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 01-16-2014 |
20140309275 | Sphingosine Analogs, Compositions, and Methods Related Thereto - The disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing disease. In certain embodiments, the disclosure relates to methods of treating an infection or cancer comprising administering a pharmaceutical composition disclosed herein to a subject in need thereof. In a typical embodiment, one administers a pharmaceutical composition comprising sphingosine or a sphingosine analog to a subject at risk for, exhibiting symptoms of or diagnosed with a malaria infection. | 10-16-2014 |
20150080450 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 03-19-2015 |
20150126577 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 05-07-2015 |
20150141482 | 1-(p-tolyl)cyclopropyl substituted Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists - The present invention relates to 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives of formula (I), | 05-21-2015 |
20150141483 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND - The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases. | 05-21-2015 |
20150297562 | ANALGESIC - An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing at least one member selected from a trans-2-decenoic acid derivative represented by the formula (1) and a pharmaceutically acceptable salt thereof as an active ingredient: | 10-22-2015 |
20160038461 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF - Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. | 02-11-2016 |
20160176816 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | 06-23-2016 |
20180021300 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS | 01-25-2018 |